Please upgrade your browser.
Dr. Brian Schuch weighs in on genetic testing for kidney cancer.
It is estimated there will be 73,820 individuals diagnosed with kidney cancer this year and 14,770 will succumb to their disease. This article discusses the top medications used to treat kidney cancer.
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell carcinoma (RCC).
ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.
Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator Award recipient supported by the Kidney Cancer Association, was involved in this breakthrough finding.
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.
ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
Meeting combined exercise guidelines – including both aerobics and strength training – improved quality of life in #KidneyCancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.
Merck announced yesterday that new combination and monotherapy data from the company’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.
Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.
|Powered by NeonCRM|